Ginkgo bioworks partners with boehringer ingelheim to develop breakthrough therapies for hard-to-treat diseases

Boston , may 8, 2023 /prnewswire/ -- ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, today announced a new partnership with boehringer ingelheim. the two companies will leverage ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery.
DNA Ratings Summary
DNA Quant Ranking